Title : Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.

Pub. Date : 2012 Mar

PMID : 22238366






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal phase II trial in patients with chronic myelogenous leukemia due to its potent activity against BCR-ABL. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens